BNP Paribas Financial Markets Portfolio holdings
BNP Paribas Financial Markets, a core component of BNP Paribas’s Corporate & Institutional Banking (CIB) division, is a global leader in trading and market-making, headquartered in Paris with major hubs in London, New York, Hong Kong, and Singapore. Specializing in derivatives across all asset classes—equities, fixed income, commodities, and foreign exchange—it provides innovative investment, hedging, and financing solutions to corporate clients, institutional investors, and financial institutions worldwide. Known for its advanced technological infrastructure and quantitative expertise, the division excels in structured financing and electronic trading, supported by a robust balance sheet and a diversified business model that proved resilient during the 2008 financial crisis. With a presence in over 50 countries and a client base exceeding 13,000, BNP Paribas Financial Markets drives market liquidity and offers cutting-edge research and execution services, reinforcing its position as a top-tier player in global capital markets.
Top Buys
| 1 |
Microsoft
MSFT
|
+$629M |
| 2 |
iShares iBoxx $ High Yield Corporate Bond ETF
HYG
|
+$380M |
| 3 |
Apple
AAPL
|
+$369M |
| 4 |
Bristol-Myers Squibb
BMY
|
+$226M |
| 5 |
iShares iBoxx $ Investment Grade Corporate Bond ETF
LQD
|
+$161M |
Top Sells
| 1 |
Invesco QQQ Trust
QQQ
|
+$1.69B |
| 2 |
SPDR S&P 500 ETF Trust
SPY
|
+$893M |
| 3 |
Industrial Select Sector SPDR Fund
XLI
|
+$361M |
| 4 |
iShares Russell 2000 ETF
IWM
|
+$321M |
| 5 |
iShares JPMorgan USD Emerging Markets Bond ETF
EMB
|
+$148M |
Sector Composition
| 1 | Technology | 19.91% |
| 2 | Consumer Discretionary | 9.64% |
| 3 | Healthcare | 9.47% |
| 4 | Financials | 9.13% |
| 5 | Communication Services | 5.54% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1026
Halozyme
HALO
$8.99B
| $2.63M | ﹤0.01% |
59,845
+14,454
| +32% | +$636K |
|
1027
RH
RH
$4.08B
| $2.63M | ﹤0.01% |
12,376
-5,409
| -30% | -$1.15M |
|
1028
Vistra
VST
$71.1B
| $2.63M | ﹤0.01% |
114,931
-124,817
| -52% | -$2.85M |
|
1029
Brixmor Property Group
BRX
$8.57B
| $2.6M | ﹤0.01% |
128,589
-299,674
| -70% | -$6.06M |
|
1030
Morningstar
MORN
$10.8B
| $2.58M | ﹤0.01% |
10,680
-304
| -3% | -$73.5K |
|
1031
Schneider National
SNDR
$4.18B
| $2.58M | ﹤0.01% |
115,280
-55,756
| -33% | -$1.25M |
|
1032
BWX Technologies
BWXT
$15.4B
| $2.57M | ﹤0.01% |
46,732
-37,112
| -44% | -$2.04M |
|
1033
Intellia Therapeutics
NTLA
$1.23B
| $2.57M | ﹤0.01% |
49,680
-10,261
| -17% | -$531K |
|
1034
Associated Banc-Corp
ASB
$4.35B
| $2.57M | ﹤0.01% |
140,772
+89,500
| +175% | +$1.63M |
|
|
COUP
1035
DELISTED
Coupa Software Incorporated
COUP
| $2.57M | ﹤0.01% |
45,001
-58,185
| -56% | -$3.32M |
|
1036
Energy Recovery
ERII
$764M
| $2.56M | ﹤0.01% |
132,002
+21,431
| +19% | +$416K |
|
1037
CVR Energy
CVI
$3.13B
| $2.55M | ﹤0.01% |
76,027
-28,129
| -27% | -$942K |
|
1038
Embraer
ERJ
$10.5B
| $2.53M | ﹤0.01% |
288,437
-103,805
| -26% | -$911K |
|
1039
Sabra Healthcare REIT
SBRA
$4.57B
| $2.53M | ﹤0.01% |
181,012
+121,169
| +202% | +$1.69M |
|
1040
Vicor
VICR
$2.28B
| $2.52M | ﹤0.01% |
46,115
-38,685
| -46% | -$2.12M |
|
1041
Quanex
NX
$661M
| $2.52M | ﹤0.01% |
110,933
+4,494
| +4% | +$102K |
|
|
SWCH
1042
DELISTED
Switch, Inc. Class A Common Stock
SWCH
| $2.52M | ﹤0.01% |
75,308
-248,987
| -77% | -$8.34M |
|
1043
New Jersey Resources
NJR
$4.74B
| $2.51M | ﹤0.01% |
56,473
+15,829
| +39% | +$705K |
|
1044
Sonoco
SON
$4.71B
| $2.51M | ﹤0.01% |
44,061
+20,561
| +87% | +$1.17M |
|
1045
iShares US Telecommunications ETF
IYZ
$607M
| $2.51M | ﹤0.01% |
+100,000
| New | +$2.51M |
|
1046
Group 1 Automotive
GPI
$6.03B
| $2.51M | ﹤0.01% |
14,775
+8,021
| +119% | +$1.36M |
|
1047
GoPro
GPRO
$327M
| $2.5M | ﹤0.01% |
451,812
-46,479
| -9% | -$257K |
|
1048
Mersana Therapeutics
MRSN
$35.6M
| $2.49M | ﹤0.01% |
21,588
-4,517
| -17% | -$522K |
|
|
RETA
1049
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $2.49M | ﹤0.01% |
81,972
+24,938
| +44% | +$758K |
|
1050
Jazz Pharmaceuticals
JAZZ
$7.65B
| $2.49M | ﹤0.01% |
15,947
-8,781
| -36% | -$1.37M |
|